Clinical trials: Stereotactic Body Radiation Therapy
HCC - Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study
Hepatocellular carcinoma (HCC) is one of the commonest cancers worldwide and ranks the third on the incidence of cancer-related death. There are more than 500000 new cases diagnosed annually worldwide.
- Trial name
- NCT07305428
- Testing
- Stereotactic Body Radiation Therapy followed by Immunotherapy
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- The University of Hong Kong
Non Small Cell Lung Cancer
Stereotactic Body Radiation Therapy for Un-biopsied Early- Stage Non Small Cell Lung Cancer
Lung cancer is the leading cause of cancer death in both men and women in the United States. In 2014, an estimated 224,210 men and women were diagnosed with carcinoma of the lung and bronchus, resulting in 159,260 deaths.
- Trial name
- NCT02950337
- Testing
- Group 1: Peripherally Located Tumors, Group 2: Peripherally Located Chest Wall Adjacent Tumors, Group 3: Centrally Located Tumors
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Loyola University
Carcinoma, Hepatocellular
TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer
Vast majority of patients with hepatocellular carcinoma (HCC) present with unresectable disease. In the last decade results of randomized trials and a subsequent metaanalyses established transarterial chemoembolization (TACE) or…
- Trial name
- TACE-SBRT (NCT02794337)
- Testing
- SBRT, TACE, Sorafenib
- Where
- 2 sites in India
- Volunteers
- 67 people
- Sponsor
- Tata Memorial Hospital
HR-positive,HER2-negative Breast Cancer
Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.
This study is the first to explore the clinical study of neoadjuvant radiotherapy followed by chemotherapy combined with terriplizumab in breast cancer.
- Trial name
- NCT06705127
- Testing
- TORIPALIMAB INJECTION(JS001 ), Stereotactic Body Radiation Therapy (SBRT)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Hepatocellular Carcinoma
Sequential Treatment of Hepatocellular Carcinoma by Transarterial Chemoembolization and Local Ablation or External Radiation
Hepatocellular carcinoma (HCC) can present itself in many forms (size, number of lesions) for the treatment of which a therapeutic panel can be elaborated and layered.
- Trial name
- CELPerCutCHC (NCT04813861)
- Where
- France
- Volunteers
- 57 people
- Sponsor
- Central Hospital, Nancy, France
Solid Tumors With Oligometastatic Spread
5 Fraction Stereotactic Body Radiation Therapy for Oligometastases Regimen, for Extra-Cranial Oligometastases
This is a prospective Phase II study.The purpose of this study is to monitor the side effects and treatment outcomes of delivering higher doses of radiation therapy to the tumour, while limiting the dose of radiation to the…
- Trial name
- 5fr SBRT (NCT01761929)
- Testing
- Radiation: 50Gy in 5 fr (max) to 25 Gy in 5 fr (min). Dose adapted to deliver the highest dose level while respecting normal tissue tolerance
- Where
- Canada
- Volunteers
- 138 people
- Sponsor
- University Health Network, Toronto
Liver Cancer
NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver Cancers
The purpose of this Phase I / II study is to evaluate the safety and preliminary efficacy of NBTXR3 nanoparticles given by intralesional (IL) or intraarterial (IA) injection and activated by Stereotactic Body Radiation Therapy in…
- Trial name
- NCT02721056
- Testing
- NBTXR3, IL or IA injection + SBRT
- Where
- 7 sites in France
- Volunteers
- 23 people
- Sponsor
- Nanobiotix
Spinal Neoplasms
Evaluation of Effectiveness of CyberKnife Stereotactic Radiosurgery for Spinal Tumors
This study aims to explore the reliability of the combination of functional magnetic resonance imaging and radiomics for evaluation of the therapeutic efficacy of CyberKnife stereotactic radiosurgery for spinal tumors.
- Trial name
- NCT04192383
- Testing
- Cyberknife stereotactic radiosurgery
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Third Hospital
Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration
Safety & Tolerability of the IRay System in Subjects With Exudative Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
The purpose of this study is to evaluate the safety and clinical feasibility of the IRay System for the treatment of wet age-related macular degeneration (AMD).
- Conditions
- Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration, Macular Degeneration, Eye Diseases
- Trial name
- NCT01217762
- Testing
- IRay
- Where
- Mexico
- Volunteers
- 62 people
- Sponsor
- Oraya Therapeutics, Inc.
Peritoneal Carcinomatosis, Oligometastatic Disease
MRI-Guided Adaptive Radiotherapy for Limited Peritoneal Metastases (MARACAS Trial).
This prospective phase II study evaluates the efficacy and safety of MRI-guided stereotactic body radiotherapy (MRIgSBRT) in patients with oligometastatic peritoneal carcinomatosis from gastrointestinal or gynecological tumors.
- Conditions
- Peritoneal Carcinomatosis, Oligometastatic Disease, Peritoneal Metastases
- Trial name
- MARACAS (NCT07593261)
- Testing
- MRI-guided stereotactic body radiotherapy
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Brain Metastases, Chemotherapy
HFSRT With Concurrent TMZ for Large BMs
A multi-center randomized phase III trial was conducted to investigate the feasibility and safety of adding temozolomide to hypofractionated stereotactic radiotherapy for large brain metastases.
- Conditions
- Brain Metastases, Chemotherapy, Radiotherapy
- Trial name
- NCT03778541
- Testing
- Temozolomide, hypofractionated radiotherapy
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Chinese Academy of Medical Sciences
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
This phase III trial studies how well atezolizumab added to the usual radiation therapy works in treating patients with stage I-IIA non-small cell lung cancer.
- Conditions
- Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
- Trial name
- NCT04214262
- Testing
- Atezolizumab, Biospecimen Collection, Computed Tomography
- Where
- 390 sites in United States
- Volunteers
- 417 people
- Sponsor
- National Cancer Institute (NCI)
Bone Metastases, Radiotherapy Side Effect
A Prospective Randomized Trial of High Dose Versus Standard Dose Stereotactic Radiotherapy for Pain Control in Patients With Bone Metastases
In the present study, we will prospectively evaluate the pain response and treatment failure rate to determine the most favorable radiation dose in single fraction stereotactic radiotherapy using the modern highly conformal…
- Trial name
- NCT04063254
- Testing
- Stereotactic Radiotherapy
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Renal Cell Carcinoma
Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer
All patients will receive IL-2 (14 planned doses with an additional cycle 14 days after the first). Responding patients with regressing disease are eligible for up to 6 IL-2 cycles.
- Trial name
- NCT02306954
- Testing
- High Dose IL-2, SBRT
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Providence Health & Services
Breast Cancer Early Stage Breast Cancer (Stage 1-3), SBRT
A Phase I Dose-escalation Trial of Definitive Single Dose Stereotactic Body Radiotherapy in Low-risk Breast Cancer Patients: DESERT I Trial
Radiotherapy (RT) is a fundamental pillar in the fight against cancer. In the case of breast cancer, RT has traditionally been applied as an adjuvant treatment following surgery.
- Trial name
- DESERT-I (NCT06671691)
- Testing
- SBRT level I, SBRT level II, SBRT level III
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Universitat de les Illes Balears
Pancreatic Cancer
MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC
The MASPAC trial investigates the added benefit of MR-guided adaptive SBRT of the primary tumor embedded between standard chemotherapy cycles for pain control and prevention of pain in patients with metastatic PDAC (mPDAC).
- Trial name
- MASPAC (NCT05114213)
- Testing
- SBRT, SOC chemotherapy
- Where
- 3 sites in Germany, Switzerland
- Volunteers
- 9 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Non Small Cell Lung Cancer, Pulmonary Stereotactic Radiotherapy
Stereotactic Body Radiotherapy (SBRT) for Reirradiation of Inoperable Lung Lesions
Radiotherapy (radiation treatment) is often used to treat lung cancers and lung tumors that have spread from other cancers. It can be very effective, especially in early-stage lung cancer or when there are only a few tumor sites.
- Trial name
- NCT07401615
- Where
- 11 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Istituto Clinico Humanitas
Head and Neck Neoplasms
Stereotactic Radiotherapy for Sinonasal Malignancy
Sinonasal Tumors are a rare type of head and neck tumor, accounting for approximately 3% of head and neck cancers. Treatment primarily involves surgical intervention, with radiation therapy as an adjunct.
- Trial name
- NCT06617910
- Testing
- SBRT by Cyberknife
- Where
- Taiwan
- Volunteers
- 16 people
- Sponsor
- Taichung Veterans General Hospital
Renal Cancer
Stereotactic Radiotherapy for Renal Cancers
Stereotactic radiotherapy is a technique that allows the delivery of a high dose of radiation over few fractions (3-6) with great precision. It thus allows "tumor ablation" and optimal preservation of healthy tissues.
- Trial name
- RSR-1 (NCT02811250)
- Testing
- Stereotactic radiotherapy 4 x 8 Gy, Stereotactic radiotherapy 5 x 8 Gy, Stereotactic radiotherapy 4 x 10 Gy
- Where
- 2 sites in France
- Volunteers
- 13 people
- Sponsor
- Hospices Civils de Lyon
Hepatocellular Carcinoma, SBRT
SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma
This is a Phase II , Open-label , Investigator-initiated Trail of SBRT in Combination With Adbelimumab and Apatinib in Patients With Hepatocellular Carcinoma(HCC).This study aims to evaluate the safety and efficacy of SBRT in…
- Conditions
- Hepatocellular Carcinoma, SBRT, Immune Checkpoint Blockade, Tyrosine Kinase Inhibitor
- Trial name
- NCT06538935
- Testing
- adbelimumab, SBRT, apatinib
- Volunteers
- 80 people
- Sponsor
- Fujian Cancer Hospital